Patients receiving a kidney transplant and who are positive for BK virus (BKV) are at risk of losing their transplant due to BKV reactivation. At this time, there are no antiviral options available ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

Oblimersen sodium (Genasense™) is an antisense oligodeoxynucleotide specific for the antiapoptotic protein Bcl-2, which could enhance the sensitivity of leukemic cells to chemotherapy in this ...

Leal Therapeutics raised $45 million for drug development, including advancing a promising therapy into clinical trials for ...

Initially touted as an innovative by GlobalData’s analysts, Amylyx’s antisense therapy Relyvrio failed to achieve its endpoints in a Phase III study (NCT05021536) for ALS. The company formally ...

our antisense therapy could become a first- and best-in-class treatment option for patients with wet AMD and/or DME,” she added. ISTH0036 may offer a true alternative to current standard of care ...

AiCuris Anti-infective Cures has launched a first-in-human Phase I trial of AIC468, an antisense oligonucleotide designed to ...

immunogene therapy. The proof-of-concept study showed that antisense oligonucleotides developed by the researchers successfully restored cellular development and brain cell function in patients ...

GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson & Johnson that had been ...

Antisense medicines target RNA ... For pelacarsen, I noted in May that "the therapy treats elevated lipoprotein, and could secure approval to treat multiple cardiovascular diseases, taking ...

A specialized treatment called a Gapmer antisense oligonucleotide (ASO ... while keeping normal gene function intact. Using this RNA therapy led to a notable decrease in a problematic potassium ...

Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of ...